[Prevention of stroke in atrial fibrillation].
Unidad de Ictus, Servicio de Neurología, Hospital Ramón y Cajal, Madrid, Spain. jmasjuan.hrc@salud.madrid.org
J
J
Masjuan
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D001562:Benzimidazoles; D000069604:Dabigatran; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D019934:International Normalized Ratio; D020766:Intracranial Embolism / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D009200:Myocardial Contraction / Q000187:drug effects; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D019851:Thrombophilia / Q000188:drug therapy* / Q000209:etiology; D015091:beta-Alanine / Q000031:analogs & derivatives
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D015091:beta-Alanine; D000069604:Dabigatran